Will A US FDA Advisory Committee Be In Intercept's Future?

 
• By Derrick Gingery

There are strong reasons to justify an advisory committee meeting for the NASH application, but also an outlet for the US FDA to skip it.

Liver infection
Several factors point toward the FDA making the product one of the minority of applications receiving an advisory committee meeting in 2019. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers